反应 #130

ord-d012fdccb17647d4838efd4e1491311e

反应方程式

CNC(=O)c1ccccc1Nc1cc(Cl)ncc1C#N
CNC(=O)c1ccccc1Nc1cc
COc1cc(N)n(C)n1
COc1cc(N)n(C)n1
CNC(=O)c1ccccc1Nc1cc(Nc2cc(OC)nn2C)ncc1C#N
CNC(=O)c1ccccc1Nc1cc
收率 54.7%

溶剂

反应条件

温度
90°CELSIUS

实验过程

2-(2-chloro-5-cyanopyridin-4-ylamino)-N-methylbenzamide (100 mg, 0.35 mmol), Palladium(II) acetate (6.26 mg, 0.03 mmol), [Reactants], 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene (24.22 mg, 0.04 mmol) and Cesium carbonate (136 mg, 0.42 mmol) were suspended in dioxane (3 mL) into a test tube. The reaction was purged for 5 mins with nitrogen and then heated to 90 °C for 18 hours with stirring. The reaction was cooled to cooled to RT. The crude product was purified by ion exchange chromatography, using an SCX column. The desired crude product was eluted from the column using 7M NH3/MeOH and fractions were evaporated to dryness to afford crude product .The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5µ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 2-(5-cyano-2-(3-methoxy-1-methyl-1H-pyrazol-5-ylamino)pyridin-4-ylamino)-N-methylbenzamide (72.0 mg, 54.7 %) as a beige solid.

来源

750 AstraZeneca ELN dataset